Venkat et al. [95] reported that treatment with EVs isolated from human-cord-blood-derived CD133+ stem cells could attenuate post-stroke cardiac dysfunction in T2D-stroke mice through decreasing the myocardial cross-sectional area and interstitial fibrosis, downregulation of the level of transforming growth factor beta (TGF-β) and the number of type 1 macrophages (M1), and upregulation of miR-126 expression in the heart of T2D-stroke mice [95]. The gene discussed is PROM1; the disease is stroke disorder.